-
Product Insights
NewPlague – Drugs In Development, 2024
Empower your strategies with our Plague – Drugs In Development, 2024 report and make more profitable business decisions. Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents, or when human handle infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock, and bleeding from the mouth, nose, ectum, or under the skin. Treatment includes...
-
Product Insights
NewPemphigus – Drugs In Development, 2024
Empower your strategies with our Pemphigus – Drugs In Development, 2024 report and make more profitable business decisions. Pemphigus is is an autoimmune disease that causes blistering of the skin and the the mucous membranes inside of the mouth, nose, throat, eyes, and genitals. It is characterized by loss of normal cell-cell adhesion (acantholysis) and by the presence of pathogenic (predominantly IgG) autoantibodies reacting against epithelial adhesion molecules called desmogleins, proteins that bind skin cells to one another. When these bonds...
-
Product Insights
NewGranulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drugs In Development, 2024
Empower your strategies with our Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Drugs In Development, 2024 report and make more profitable business decisions. Wegener polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factors include age. Treatment includes immunosuppressants and corticosteroids. The Granulomatosis with Polyangiitis (Wegener's Granulomatosis) drugs in development market research report...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PHI-101 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PHI-101 in Refractory Acute Myeloid Leukemia Drug Details:PHI-101 is under development for the treatment of relapsed...
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Company Profile
iBio Inc – Company Profile
iBio Inc (iBio) is a preclinical-stage biotechnology company that utilizes artificial intelligence (AI) for the development of precision antibodies. Its pipeline products include IBIO-101 for the indication of solid tumors. The company's other oncology and autoimmune programs comprise Trop-2 x CD3, -MUC16, EGFRvIII and PD-1 for the treatment of multiple solid tumors, including breast, lung, colorectal and pancreatic cancers, glioblastoma, rheumatoid arthritis and other inflammatory diseases. iBio platform includes its patented epitope-steering AI engine, StableHu technology, a machine learning-based antibody-optimizing,...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....
-
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...